SCHEMBL4291487

SCHEMBL4291487

CCNCCC(=O)Nc1ccc2c(c1)C(=O)c1cc(NC(=O)CCNCC)ccc1C2=O

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TERT O14746 17/20 0.74
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
ALDH1A1 P00352 1/20 0.62
CYP1A2 P05177 1/20 0.62
POLB P06746 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
MAPT P10636 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
RAB9A P51151 1/20 0.62
KMT2A Q03164 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
PTPRC P08575 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4298186 0.90 PTPRC (0.64) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4289808 0.87 PTPRC (0.61) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL10526549 0.85 TERT (1.00) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4291481 0.85 TERT (1.00) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4298269 0.84 PTPRC (0.83) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4299908 0.81 ALDH1A1 (0.90) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4297885 0.79 TERT (0.78) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL13663715 0.79 PTPRC (0.74) TERTMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4294857 0.78 CASP3 (0.74) TERTPTPRC
SCHEMBL9629661 0.78 CASP3 (0.74) TERTPTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES NATIONAL DEFENSE MEDICAL CENTER (TW) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253709-A1 SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES TERT, NAT10, POT1 TERT 1/4885MEN1 148/4885NPC1 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.